VIRIOS THERAPEUTICS INC (VIRI)       0.2846  0 (-1.62%)

0.2846  0 (-1.62%)

US92829J1043 - Common Stock

VIRIOS THERAPEUTICS INC0.2846

NASDAQ:VIRI (12/6/2022, 7:09:56 PM)0 (-1.62%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-14 2022-11-14/bmo Earnings (Next) N/A N/A
Ins Owners 4.92% Inst Owners 7.04%
Market Cap 5.22M Shares 18.33M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 43.33
IPO 12-17 2020-12-17

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

VIRI Daily chart

Company Profile

Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. The company is headquartered in Alpharetta, Georgia and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The Company’s lead development candidate is IMC-1, which is a fixed dose combination of famciclovir, and celecoxib designed to synergistically suppress herpes virus replication. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication. The Company’s pipeline product includes IMC-2 (valacyclovir and celecoxib), which is in the Phase 1 development stage. IMC-2 (valacyclovir and celecoxib) is developed for treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with Long-COVID or Post-Acute Sequelae of COVID-19 (PASC).

Company Info

VIRIOS THERAPEUTICS INC

44 Milton Avenue

Alpharetta GEORGIA

P: 18666208655.0

Employees: 5

Website: https://www.virios.com/

VIRI News

News Image8 days ago - Virios Therapeutics, Inc. (VIRI)Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap ShowcaseNews Image23 days ago - Virios Therapeutics, Inc.Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateNews Imagea month ago - Virios Therapeutics, Inc. (VIRI)Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022News Image3 months ago - Virios Therapeutics, Inc.Virios Therapeutics, Inc. Announces Closing of Public OfferingNews Image3 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time for an overview of the biggest pre-market stock movers for Thursday and all the news behind this morning's movement.

VIRI Twits

Here you can normally see the latest stock twits on VIRI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example